Literature DB >> 24831172

Performance of EGFR mutant-specific antibodies in different cytological preparations: a validation study.

C Bellevicine1, A Bianco, U Malapelle, C De Luca, E Vigliar, N A Cacciola, P Pallante, G Troncone.   

Abstract

OBJECTIVES: Molecular testing for epidermal growth factor receptor (EGFR) mutations is required to select the most appropriate treatment for advanced-stage non-small cell lung cancer (NSCLC). In routine practice, cytological samples are often the only specimens available for testing. When the number of neoplastic cells is large, DNA-based assays are the gold standard. When cytological samples contain only a few neoplastic cells, immunocytochemistry (ICC) using anti-EGFR mutant-specific antibodies may be more effective. We aim to assess the specificity and sensitivity of IHC staining in cytological specimens using mutated cell lines subjected to different cytopreparations and staining methods.
METHODS: HCC827 (exon 19 p.E746-A750 del) and H3255 (exon 21 p.L858R) cell lines were subjected to different fixation (air dried, alcohol or CytoLyt(®)), staining (Diff-Quik(®) or Papanicolaou) and preparation (smears or cell blocks) methods before ICC. In a second set of experiments, mutated cells were mixed with EGFR wild-type cells to obtain low-level (10%) mutated cytological samples. The intensity and percentage of cells stained were evaluated against validated molecular techniques. Moreover, the cell lines were subjected to poor growing conditions to simulate routine specimens that are less optimal than in vitro samples.
RESULTS: The cytological preparations showing the most intense staining were formalin-fixed cell blocks and samples fixed with CytoLyt or alcohol, including Papanicolaou-destained samples. Conversely, air-dried slides showed the least intense staining. Mutant antibodies allowed the detection of mutated cells, even when representing only 10% of the total population. Although, in necrotic specimens, an aspecific background signal appeared, the viable cells still retained anti-mutant EGFR positivity.
CONCLUSIONS: All cytological preparations are suitable for ICC using anti-EGFR mutant-specific antibodies, in particular formalin-fixed cell blocks and alcohol- or CitoLyt-fixed samples. the method is also validated to detect even a few mutant cells in less than optimal samples.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  EGFR mutations; immunocytochemistry; molecular biology; mutation-specific antibodies; non-small cell lung cancer

Mesh:

Substances:

Year:  2014        PMID: 24831172     DOI: 10.1111/cyt.12155

Source DB:  PubMed          Journal:  Cytopathology        ISSN: 0956-5507            Impact factor:   2.073


  4 in total

1.  Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections.

Authors:  Giuseppe Pelosi; Federica Perrone; Elena Tamborini; Alessandra Fabbri; Maria Adele Testi; Adele Busico; Giulio Settanni; Benedetta Picciani; Enrica Bovio; Angelica Sonzogni; Barbara Valeri; Marina Garassino; Filippo De Braud; Ugo Pastorino
Journal:  Virchows Arch       Date:  2016-01-27       Impact factor: 4.064

Review 2.  Immunocytochemistry for predictive biomarker testing in lung cancer cytology.

Authors:  Deepali Jain; Aruna Nambirajan; Alain Borczuk; Gang Chen; Yuko Minami; Andre L Moreira; Noriko Motoi; Mauro Papotti; Natasha Rekhtman; Prudence A Russell; Spasenija Savic Prince; Yasushi Yatabe; Lukas Bubendorf
Journal:  Cancer Cytopathol       Date:  2019-05-03       Impact factor: 5.284

3.  Targeted sequencing with enrichment PCR: a novel diagnostic method for the detection of EGFR mutations.

Authors:  Suki Kang; Baek Gil Kim; Hyun Ho Han; Joo Hyun Lee; Ji Eun Kim; Hyo Sup Shim; Nam Hoon Cho
Journal:  Oncotarget       Date:  2015-05-30

4.  Development of an immuno-wall device for the rapid and sensitive detection of EGFR mutations in tumor tissues resected from lung cancer patients.

Authors:  Naoyuki Yogo; Tetsunari Hase; Toshihiro Kasama; Keine Nishiyama; Naoya Ozawa; Takahiro Hatta; Hirofumi Shibata; Mitsuo Sato; Kazuki Komeda; Nozomi Kawabe; Kohei Matsuoka; Toyofumi Fengshi Chen-Yoshikawa; Noritada Kaji; Manabu Tokeshi; Yoshinobu Baba; Yoshinori Hasegawa
Journal:  PLoS One       Date:  2020-11-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.